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ABSTRACT- The distribution of calcitonin gene-related peptide (CGRP) im- 
munoreactivity in the cavernous tissue and the erectile response to intracaver- 
nous injection of CGRP was investigated in 7 monkeys. Intracavernous CGRP 
increased cavernous arterial flow and induced cavernous smooth muscle relax- 
ation and venous outflow occlusion. Intracavernous injection of CGRP anti- 
body did not significantly change the erectile response to cavernous nerve stim- 
ulation. Histologic staining for CGRP immunoreactivity showed nerve 
fiber-like staining within the cavernous arterial wall and the cavernous smooth 
muscles. These data suggest that CGRP may contribute to penile erection in 
monkeys. 
In 1863 Eckhard’ reported that canine penile 
erection could be induced by stimulation of 
pelvic parasympathetic nerves. Although ace- 
tylcholine is the presumed postganglionic para- 
sympathetic neurotransmitter,” Anrep and Cy- 
bulsky3 showed about a hundred years ago, that 
penile erection is atropine-resistant. The latter 
findings were confirmed in many other stud- 
ies 4-12 
More recently, we reported that nerve-stimu- 
lation-induced erections in monkeys and dogs 
could be reduced, but not abolished after mus- 
carinic blockade by intracavernous injection of 
atropine. 13x14 These data showed that acetylcho- 
line was only partly responsible for penile erec- 
tion, suggesting the presence of additional 
postganglionic parasympathetic neurotransmit- 
ters. A candidate for this noncholinergic para- 
sympathetic neurotransmitter is calcitonin 
gene-related peptide (CGRP),15 a potent vaso- 
dilatorle-l* and smooth muscle relaxant. 1e-22 
High concentrations of immunoreactive CGRP 
are found in penile tissue of the rat.23 In this in 
vivo study, we examined functionally and histo- 
logically the contribution of CGRP to penile 
erection in monkeys. 
Material and Methods 
Seven pigtail monkeys, weighing 4.3 to 8.3 
kg, were used. After adequate anesthesia with 
ketamine (30 mg/kg body weight i.m.), the 
monkeys were placed in the supine position. 
Under sterile conditions, a 21-gauge scalp-vein 
needle was placed bilaterally in the distal cav- 
ernous body. One needle was connected to a 
Statham transducer (model P23 BC) for intra- 
cavernous pressure recording (Grass Polygraph; 
model 7); the other was used for intracavernous 
injection or perfusion. Penile tumescence was 
visually monitored by two investigators and re- 
corded; classification of tumescence was done 
according to the following parameters: E-O = 
no tumescence; E-l = slight tumescence; E-2 
= partial tumescence; E-3 = full tumescence. 
The flow through the cavernous arteries was 
measured in 4 monkeys by duplex ultrasound.24 
Pulse and blood pressure were monitored 
closely with the aid of a Doppler probe (Parks 
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FIGURE 1. Schematic shows experimental set-up. 
Medical Electronics) on the radial artery and a 
pediatric blood pressure cuff. 
Intracavernous injection of CGRP 
In a pilot study, we injected 50, 500, and 
2,500 ng CGRP intracavernously in 2 monkeys. 
A total of 50 ng CGRP induced only a slight, 
short-lasting tumescence. Because the intra- 
cavernous injection of 2,500 ng CGRP lowered 
the systemic blood pressure by about 35 cm 
HzO, and the erectile response was similar (only 
longer lasting) to the response to 500 ng, a dose 
of 500 ng CGRP was chosen for the following 
study. 
All monkeys received a dose of 500 ng CGRP 
(Sigma Chemical Co., St. Louis, MO) by intra- 
cavernous injection. To verify reproducibility, 
the injection was repeated on a second day. 
Effect of CGRP on cavernous outflow 
In all monkeys, the penis was perfused with 
saline (37°C) at a rate of 26.7 mL/min before 
and one minute after 500 ng CGRP intracaver- 
nously. When the perfusion had continued for 
sixty seconds or the intracavernous pressure sur- 
passed 300 cm Hz0 (off scale), it was stopped. 
After a five-minute period, the penis was reper- 
fused. The perfusion series was stopped when 
two subsequent perfusions evoked responses 
equal to that prior to the intracavernous injec- 
tion of CGRP 
Erections induced by neurostimulation before 
and after CGRP-antibody 
In 6 monkeys, cuff electrodes were placed 
around the cavernous nerve as previously 
described.25 After three erections had been in- 
duced by neurostimulation (20 Hz, 6 to 8 V, 
stimulation time = 1 minute), 500 ng CGRP- 
antibody (Penninsula Lab.) were injected intra- 
cavernously and neurostimulation was repeated 
after one minute and then three times with an 
eight-minute interval between each stimulation 
(Fig. 1). 
Histologic staining for 
CGRP-immunoreactivity 
In 2 monkeys, the aorta was clamped and the 
cavernous bodies were perfused with 500 mL 
saline, followed by 500 mL phosphate buffer 
(0.1 M) and fixed with 500 mL phosphate buf- 
fered 4% paraformaldehyde. All perfusion so- 
lutions were at 4 “C. The cavernous bodies were 
removed and sections of approximately 0.5 cm 
long were placed in the fixation solution for 
thirty minutes at 4°C. After overnight rinsing 
in 30 % sucrose, the tissues were embedded (Tis- 
sue Tek, Miles Scientific, Naperville, IL) and 
frozen. 
An indirect immunofluorescence technique 
was used to locate CGRP-immunoreactive fi- 
bers.26 Cryostat sections were cut (16 pm) and 
placed on lycine-coated slides. The sections 
were rehydrated with buffer (0.05M PBS + 
0.3% Triton-X 100, pH 7.4) for five minutes, 
then preincubated at room temperature for 
thirty minutes with 5% goat serum in buffer. 
After draining but not rinsing, the sections were 
incubated in a humidified chamber for forty- 
eight to seventy-two hours at 4 “C with an anti- 
body to CGRP raised in rabbits (Penninsula 
Lab., San Carlos, CA), dilution 1:lOO. After 
three ten-minute washes in buffer, the slides 
were incubated for thirty minutes at 37°C in 
goat anti-rabbit IgG conjugated to fluorescein- 
isothiocyanate (FITC) (Cooper Biomedical, 
Malvern, PA) diluted 1:50. The sections were 
then washed, mounted with glycerol:PBS (9:l) 
containing 1.5% 1,4-Diazabicyclo [2.2.2] oc- 
tane, pH 8.6 (DABCO, Sigma Chemical), and 
viewed with an Olympus microscope equipped 
for viewing FITC fluorescence. As method con- 
trol, tissues were prepared as mentioned, but 
without adding CGRP-antibody. Statistical 
analysis was done using the Student t-test. 
Results 
Zntracavernous injection of CGRP 
The first change after the intracavernous in- 
jection of 500 ng CGRP was an increase in arte- 
rial flow. This was followed by penile tumes- 
cence, and then after about one minute, by an 
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‘acavernoUS injection of CGRP, 
within cavernous artery was 
increase in intracavernous pressure. Prior to in- 
tracavernous injection of CGRP, we could not 
measure flow velocity of the cavernous artery 
by duplex ultrasound. After intracavernous in- 
jection of CGRP, there was a gradual increase 
in flow velocity. The flow velocity of the cav- 
ernous artery peaked at four minutes (mean) af- 
ter the injection of CGRP The maximum flow 
velocity diminished three to four minutes later, 
We could not detect an arterial flow thirty-two 
to sixty-nine minutes (mean 49 min) after the 
intracavernous injection of CGRP (Fig. 2). 
Penile tumescence increase was observed 
about thirty to sixty seconds after the CGRP in- 
jections. Maximal tumescence and elongation 
(E-3) was seen at the time of maximal arterial 
inflow (mean 4 min after injection) until up to 
fifteen minutes after the injection. Tumescence 
then gradually decreased; after a mean of 
thirty-two minutes, no difference between the 
tumescence before and after the injection of 
CGRP could be detected. Intracavernous pres- 
sure before CGRP-injection was twenty-four to 
forty-five cm Hz0 (mean 34). Within ninety to 
one hundred twenty seconds after the injection, 
the intracavernous pressure rose to a mean max- 
imum pressure of 62 to 94 cm Hz0 (mean 78). 
Two to four minutes later, the intracavernous 
pressure fell within less than sixty seconds to a 
mean pressure level of 40 to 54 cm Hz0 (mean 
47). This pressure gradually declined until base- 
line pressure was reached after a mean of 
thirty-six minutes. 
Effect of CGRP on cauernom outflow 
In the monkeys, saline perfusion at 26.7 mL/ 
min induced an intracavernous pressure of 
mean 143 cm Hz0 and slight penile tumescence 
and elongation (E-l). The response to saline 
perfusion one minute after the CGRP injection 
was equal to that before the injection, suggest- 
ing that the cavernous smooth muscles are still 
in the contracted state. After five minutes, sa- 
line perfusion showed full venous occlusion 
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FIGURE 3. (A) Control 
perfusion of cavernous 
body with saline alone. 
(B) Long-lasting venous 
occlusive effect shown 
after intTacavernous in- 
jection of CGRP (arrow 
at minute 0). 
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(and consequently cavernous smooth muscle re- 
laxation) with full erection in 6 of 7 monkeys; 
this lasted forty-five to eighty minutes (mean 
55). In one monkey, full venous occlusion could 
not be achieved by a perfusion rate of 26.7 mL/ 
min (Fig. 3). 
Erections induced by neurostimulation before 
and after CGRP-antibody 
In all monkeys, the erectile response to 
neurostimulation was not significantly changed 
after the intracavernous injection of 500 ng 
CGRP antibody. 
Histologic staining for 
CGRP-immunoreactivity 
In the control slides, unspecific staining was 
found within the endothelium of the arteries. 
In the slides stained for CGRP immunoreactiv- 
ity (CGRP-l), nerve fiber-like CGRP-1 was 
found within the walls of the cavernous arteries 
and within the cavernous smooth muscles. 
Dense varicosity-like staining was also found 
within the cavernous smooth muscles (Fig. 4). 
Comment 
Intracavernous injection of CGRP induced 
an erectile response. This response was due to 
an increase in arterial flow, relaxation of the 
cavernous smooth muscles, and occlusion of the 
venous outflow. The changes in the arterial 
flow were shown by Duplex sonography of the 
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FIGURES. Dense varicosity-like staining was found 
within simian cavernous smooth muscles (original 
magnification x 400). 
cavernous arteries. Relaxation of the cavernous 
smooth muscles by CGRP was demonstrated by 
penile tumescence and by the perfusion studies: 
saline perfusion alone at a rate of 26.7 mL/min 
induced a mean intracavernous pressure of 143 
cm HzO, corresponding to the intracavernous 
pressure of a full erection induced by neuro- 
stimulation.25 However, saline perfusion alone 
induced only a slight penile tumescence and 
elongation. This is probably due to contracted 
cavernous smooth muscles with subsequent in- 
complete expansion of cavernous spaces and 
therefore incomplete penile tumescence. In 
contrast, the same perfusion rate induced full 
erection after intracavernous injection of 
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CGRF? Probably, this reflects complete cavern- 
ous smooth muscle relaxation with subsequent 
cavernous outflow restriction.27 The presence of 
CGRP immunoreactive fibers in cavernous ar- 
teries and cavernous smooth muscles provide an 
anatomic base for these in vivo findings. 
Our histologic findings of CGRP-1 in cavern- 
ous arteries and smooth muscles are supported 
by the study of Wimalawansa, Emson, and 
MacIntyrg3 showing a high concentration of 
CGRP binding sites in rat penile tissue extracts. 
Arterial dilatation to CGRP in man and dif- 
ferent animal species was found in vivo16.17 and 
in vitro.ls Furthermore, other in vitro studies 
showed that CGRP is a potent relaxant of the 
smooth muscle of the intestine19 and the vas def- 
erens . 20-22 
Intracavernous injection of CGRP antibody 
did not significantly change the erectile re- 
sponse to neurostimulation. In contrast to VIP 
antibody that also has a VIP antagonistic ef- 
fect,28 CGRP antibody seems to have no CGRP 
antagonistic effect. 
Our findings suggest a possible role for 
CGRP as neurotransmitter/cotransmitter for 
penile erection. Further studies are needed to 
investigate the possibility of therapeutic appli- 
cations of CGRP in erectile dysfunction. Intra- 
cavernous application of CGRP may be tried, 
given the appropriate indication and careful 
patient selection. 
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